Algernon Pharmaceuticals Launches Research Program for Treatment of Stroke Using Psychedelic Drug DMT
Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company has launched a research program with the Psychedelic Drug DMT to see its effect on Stroke victims.
Christopher Moreau talks more about the drug known as “The Spirit Molecule” and the timeline to start clinical trials.
